Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics, BD Biosciences, Linden Bioscience, NuGen, Gene Logic

Premium

Interleukin Genetics was awarded a patent by the U.S. Patent and Trademark Office for the discovery that certain common variations in the Interleukin-1 genes are associated with an increased risk for heart disease.

Studies conducted by Interleukin Genetics have demonstrated that certain SNPs in the IL-1 genes produce a pro-inflammatory state, the company said. It explained that one pattern of IL-1 SNPs leads to “increased levels of inflammation and an increased risk of an acute myocardial infarction.”

The patent, No. 6,524,795, was awarded late last month.


BD Biosciences has announced the release of its affinity-tagged Tet-Response Vectors.

“By combining both a selection marker for direct selection of stable clones and an expression tag, these vectors provide … [a] direct way to generate and screen cell lines for inducible target-gene expression,” BD Biosciences said.

Researchers looking to select stable cell lines can choose either puromycin or hygromycin vectors. In addition, the protein “is expressed with either a purification tag (6xHN) or an epitope tag (HA or Myc),” the company said.


Linden Bioscience has launched a web-based probe-design service that gives academic and biotech labs access to its new oligo probe-designing technology TILIA.


NuGen has introduced its Ovation nanosample RNA-amplification system for gene-expression profiling on commercial and self-spotted oligo and cDNA microarrays.

The system, which uses NuGen's Ribo-SPIA RNA-amplification process, “reduces the amount of sample required for gene-expression profiling while preserving the fidelity required for meaningful analysis,” the company said.

NuGen added that one round of amplification using the Ovation system “produces microgram quantities of cDNA from total RNA samples as small as one nanogram, and provides enough material for multiple arrays or hundreds of gene-specific TaqMan assays.”


Gene Logic has released its BioExpress Inflammation Suite, the company said last week.

The suite comprises gene-expression data developed for pharmaceutical and biotechnology companies studying the genomic mechanisms of inflammatory and autoimmune diseases.

It currently contains three gene-expression content components: human tissue samples and assoc-iated clinical annotations; animal disease models; and in vitro cellular model systems.

Filed under